Search

everythinglearnresearchcommunity

for

Search:↓

A user, 42 M, NW 5-6, used oral Dutasteride, Minoxidil, RU58841 topical, micro needling, Nizoral shampoo, saw palmetto gummies, vitamin D gummies, and scalp massages for 2 months. They noticed many small light hairs on previously bald areas and are questioning if these will darken or remain vellus hairs.

The user is experiencing diffuse hair thinning after 8 months on topical finasteride and 11 months on minoxidil, and is considering switching to oral finasteride due to lack of effectiveness. They also mention scalp itchiness and use of a 1% ketoconazole shampoo.

A 27-year-old experienced significant hair regrowth after a hair transplant with 4349 grafts, supported by minoxidil and finasteride, improving his confidence. He plans to update on further progress at 9–12 months.

The user switched from topical to oral minoxidil (5mg daily) a year ago, saw no improvement, and experienced chest pain and trouble sleeping after stopping. They are considering whether to resume and taper the dosage due to stress and anxiety.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.

The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.

A doctor recommended Follivera as a minoxidil alternative, but users are skeptical, suggesting minoxidil, finasteride, or dutasteride for hair loss. Some users mention adenosine and piroctone olamine as potentially helpful ingredients.

A 29-year-old is using 1mg oral finasteride and 50mg/g topical minoxidil daily for hair loss, with plans to reduce minoxidil use due to greasiness and considering a hair transplant for receding temples. No side effects from finasteride were reported, and many users suggest a transplant may not be necessary due to good hair density.

A 26-year-old from the UK is experiencing increased hair thinning despite using dutasteride and topical minoxidil. They are considering additional treatments like ketoconazole shampoo, oral minoxidil, and possibly RU58841, while seeking advice on managing side effects and exploring other options.

Be skeptical of claims about new baldness cures; current treatments like finasteride, dutasteride, and minoxidil remain the best options. New products like Breezula and PP405 lack compelling evidence and may not be available soon.

The conversation is about a user assessing their hair loss as Norwood 1.5 and discussing their use of oral minoxidil and finasteride for 2.5 years, which improved their hair density. They are content with their current progress but hope to reach Norwood 1.

A 24-year-old male experiencing hair loss has been using finasteride, minoxidil, and ketoconazole shampoo without progress. He is considering switching to oral minoxidil and dutasteride, exploring dermarolling, and eliminating dairy from his diet.

DUPA and retrograde alopecia may not be solely DHT-based, and a biopsy is crucial for accurate diagnosis and treatment. Treatments mentioned include dutasteride, oral minoxidil, pioglitazone, clobetasol, calcipotriol, ketoconazole, and doxycycline, depending on the specific condition.

A 21-year-old is using finasteride and previously used minoxidil for hairline concerns, considering a hair transplant despite no visible balding. They are advised to continue finasteride as a preventive measure.

A man in his twenties with hereditary hair loss has been using 5% Minoxidil, a derma roller, Vitamin D3, and recently started Finasteride, noticing baby hairs and some improvement. Users encourage him, noting good progress and potential for further improvement.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

An 18-year-old using 5% minoxidil topically and derma rolling weekly for 1.5 months shows visible hair growth progress. The user also addresses vitamin D deficiency and thyroid imbalance with medication.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

The user is excited about their hair regrowth after 10 weeks using oral finasteride, topical minoxidil, ketoconazole, dermarolling, and vitamin D. They've seen significant hair thickening and believe minoxidil and dermarolling are the main contributors to their progress.

The conversation discusses the effects of using Tongkat ali and dioscorea to raise DHT levels, leading to increased body hair growth and an itchy scalp, without causing hair loss. The discussion also debates the role of DHT in male characteristics and its impact on sexual function, with differing opinions on its importance and effects.

The user is experiencing diffuse hair thinning despite using finasteride and oral minoxidil, with no hairline recession or bald spots. Suggestions include checking for telogen effluvium, considering a JAK inhibitor for potential autoimmune issues, and conducting further tests to rule out other causes.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

A 25-year-old woman has been losing hair for 10 years despite normal thyroid, hormone levels, and B12 supplementation. She has used Minoxidil with limited success and is considering hair transplants, Propecia, or shaving her head and wearing wigs.

A 24-year-old with a high Norwood scale is seeking advice on hair loss treatments and considering a second hair transplant. They currently use topical finasteride and minoxidil, castor oil, and a derma roller, and are advised to switch to oral dutasteride and minoxidil.

The user experienced negative side effects from oral minoxidil, including cardiac issues and excessive sweating, and decided to switch to topical minoxidil while using other treatments like RU58841, Setipiprant, Azelaic acid, and latanoprost. Another user suggested splitting the oral minoxidil dose to reduce side effects.

Age-linked hair loss is linked to disappearing collagen. Treatments discussed include minoxidil, finasteride, RU58841, tretinoin, microneedling, and collagen supplements.

A 25-year-old is experiencing hair loss since 2022, possibly linked to post-COVID effects, and is hesitant to use minoxidil or finasteride due to side effects. They have tried shampoos, vitamins, and scalp massages with limited success and are seeking natural solutions.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.